Family Medicine
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
16 May, 2023 | 15:04h | UTCNews Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization
WHO Guideline: Use of non-sugar sweeteners – World Health Organization
Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization
RCT | Optimizing the timing of whooping cough immunization in mums through investigating pertussis vaccination in pregnancy
16 May, 2023 | 14:49h | UTC
M-A | Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome?
16 May, 2023 | 14:44h | UTC
RCT | Colchicine ineffective for pain relief in hand osteoarthritis patients
16 May, 2023 | 14:42h | UTCColchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial – The Lancet Rheumatology (link to abstract – $ for full-text)
Commentary: Colchicine Does Not Relieve OA-Related Hand Pain Compared With Placebo – DocWireNews
Commentary on Twitter
NEW RESEARCH—@AnnaDossing and colleagues report the results of the COLOR trial; #colchicine twice a day did not relieve #pain vs placebo in people with hand #osteoarthritis https://t.co/LfKTwVONGM pic.twitter.com/jTBh076LZ6
— The Lancet Rheumatology (@TheLancetRheum) April 5, 2023
Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women
15 May, 2023 | 13:23h | UTCRelated USPSTF Statement: Screening Osteoporosis to Prevent Fractures
RCT | Rivaroxaban doesn’t reduce thrombotic events, hospitalization, or death in outpatients with COVID-19
15 May, 2023 | 13:19h | UTCSummary: The PREVENT-HD trial, a double-blind, placebo-controlled randomized study, was conducted to evaluate the effectiveness of prophylactic anticoagulation in reducing venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor. The trial took place between August 2020 and April 2022 across 14 US integrated healthcare delivery networks, with 1,284 patients enrolled and randomly assigned to receive either 10 mg of oral rivaroxaban or placebo daily for 35 days.
However, the study was terminated prematurely due to enrollment challenges and lower-than-expected event rates. The primary efficacy outcome, a composite of various hazardous events, occurred in 3.4% of the rivaroxaban group and 3.0% of the placebo group, with no significant difference between the two groups (hazard ratio, 1.16 [95% CI, 0.63–2.15]; P=0.63). No critical-site or fatal bleeding was observed, and only one patient in the rivaroxaban group experienced a major bleed.
In conclusion, rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis does not appear to reduce the composite end point of venous and arterial thrombotic events, hospitalization, and death. The study’s premature termination and lower-than-expected event rates may limit the generalizability of these findings.
Commentary on Twitter
#OriginalArticle: In this #RCT, Rivaroxaban did not appear to reduce a composite endpoint of venous and arterial thrombotic events, hospitalization, and death among non‐hospitalized patients with symptomatic COVID‐19 #AHAJournals https://t.co/PhdXnTJ0V9 pic.twitter.com/f04uYu2M5f
— Circulation (@CircAHA) May 10, 2023
RCT | Cognitive behavioral therapy proves effective for severe post-COVID-19 fatigue
15 May, 2023 | 13:16h | UTCNews Release: Cognitive behavioral therapy lessens post-viral fatigue after COVID-19 – Amsterdam UMC
Commentary on Twitter
Efficacy of Cognitive Behavioral Therapy Targeting Severe Fatigue Following COVID-19: Results of a Randomized Controlled Trial
✅ Just Accepted
? Open Access@amsterdamUMChttps://t.co/P1jwLOcfvw— Clinical Infectious Diseases (@CIDJournal) May 13, 2023
RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events
15 May, 2023 | 13:10h | UTCPhase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh#pediatrics
— NEJM (@NEJM) May 10, 2023
RCT | Neck–shoulder region training for chronic headache in women
15 May, 2023 | 12:59h | UTC
Commentary on Twitter
Neck-Shoulder Region Training for Chronic Headache in Women: A Randomized Controlled Trial
????
"The progressive exercise program almost halved headache frequency"https://t.co/HQN2yppF27 pic.twitter.com/3ZFltwJTWl
— Physio Meets Science (@PhysioMeScience) April 26, 2023
Review | Nonalcoholic fatty liver disease from a primary care perspective
15 May, 2023 | 12:57h | UTCNonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism
RCT | Transvenous occlusion of incompetent pelvic veins to treat chronic pelvic pain in women
15 May, 2023 | 12:54h | UTC
M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients
15 May, 2023 | 12:52h | UTC
Hoarding disorder: evidence and best practice in primary care
12 May, 2023 | 13:45h | UTCHoarding disorder: evidence and best practice in primary care – British Journal of General Practice
News Release: New guidance to help diagnose hoarding disorder – Anglia Ruskin University
Should my elderly hospitalized patient with acute onset of altered mental status undergo stat head CT?
12 May, 2023 | 13:38h | UTC
Cohort Study | Association between cannabis use disorder and schizophrenia stronger in young males than in females
12 May, 2023 | 13:29h | UTCNews Release: Young men at highest risk of schizophrenia linked with cannabis use disorder – National Institutes of Health
M-A | Surgical interventions for symptomatic knee osteoarthritis
12 May, 2023 | 13:26h | UTC
Cohort Study | Association between depression and physical conditions requiring hospitalization
12 May, 2023 | 13:16h | UTCAssociation Between Depression and Physical Conditions Requiring Hospitalization – JAMA Psychiatry
Commentaries:
Study IDs Link for Depression, Physical Conditions Requiring Hospitalization – HealthDay
Commentary on Twitter
In this study, the main causes of excess hospitalizations in people with depression were endocrine, musculoskeletal, and vascular diseases. https://t.co/TNaVPKqEFE
— JAMA Psychiatry (@JAMAPsych) May 3, 2023
Cohort Study | Adverse outcomes and rehospitalization more common for young women after acute myocardial infarction
11 May, 2023 | 12:18h | UTCSex Difference in Outcomes of Acute Myocardial Infarction in Young Patients – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Releases:
Commentaries:
Rehospitalizations After Acute MI: Young Women Outpace Young Men – TCTMD
Commentary on Twitter
Young women with #AMI face higher risk for repeat hospitalization after discharge compared to men. https://t.co/QC9NjCflnU#JACC #cvAMI #VIRGO #WomensHealth @MitsuakiSawano @hmkyale pic.twitter.com/iHorGCDoDF
— JACC Journals (@JACCJournals) May 6, 2023
Blood pressure variability in clinical practice: past, present and the future
11 May, 2023 | 12:13h | UTC
Aspirin for primary prevention of cardiovascular disease: what do the current USPSTF guidelines say?
11 May, 2023 | 12:11h | UTCOriginal Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.
Related Randomized Trials:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Related Meta-Analysis:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Related Opinions:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders
M-A | Intensive blood pressure control for patients aged over 60
11 May, 2023 | 12:07h | UTC
M-A | Fruit and vegetable consumption and the risk of hypertension
11 May, 2023 | 12:02h | UTC
Autism spectrum disorders in adulthood: symptoms, diagnosis, and treatment
11 May, 2023 | 11:51h | UTC
Olfactory dysfunction: etiology, diagnosis, and treatment
11 May, 2023 | 11:50h | UTCOlfactory Dysfunction: Etiology, Diagnosis, and Treatment – Deutsches Ärzteblatt International
Review | Radiation exposure in computed tomography
11 May, 2023 | 11:47h | UTCRadiation Exposure in Computed Tomography – Deutsches Ärzteblatt International